

Altus Pharmaceuticals Inc.  
Form 8-K  
January 03, 2007

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

December 29, 2006

Altus Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction  
of incorporation)

0-51711

(Commission  
File Number)

04-3573277

(I.R.S. Employer  
Identification No.)

125 Sidney Street, Cambridge, Massachusetts

(Address of principal executive offices)

02139

(Zip Code)

Registrant's telephone number, including area code:

617-299-2900

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Top of the Form**

**Item 1.01 Entry into a Material Definitive Agreement.**

On December 29, 2006, Altus Pharmaceuticals Inc. entered into two Promissory Notes with Oxford Financial Corporation. The Promissory Notes are collateralized by certain capital assets of the Company.

Under the terms of Promissory Note Schedule 08, the Company received total cash proceeds of \$671,660.87. Promissory Note Schedule 08, which bears interest at 10.34% per annum, will be repaid in 48 monthly installments of \$16,998.47.

Under the terms of Promissory Note Schedule 09, the Company received total cash proceeds of \$638,339.03. Promissory Note Schedule 09, which bears interest at 10.36% per annum, will be repaid in 36 monthly installments of \$20,528.24.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The disclosure set forth in Item 1.01 above is incorporated in this Item 2.03 by reference.

**Item 9.01 Financial Statements and Exhibits.**

10.1 Form of Promissory Note Schedule No. 08 issued to Oxford Finance Corporation, dated December 29, 2006

10.2 Form of Promissory Note Schedule No. 09 issued to Oxford Finance Corporation, dated December 29, 2006

---

Edgar Filing: Altus Pharmaceuticals Inc. - Form 8-K

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Altus Pharmaceuticals Inc.

*January 3, 2007*

By: *Jonathan I. Lieber*

---

*Name: Jonathan I. Lieber*

*Title: Vice President, Chief Financial Officer and Treasurer*

---

## Edgar Filing: Altus Pharmaceuticals Inc. - Form 8-K

**Top of the Form**

### Exhibit Index

| <b>Exhibit No.</b> | <b>Description</b>                                                                                          |
|--------------------|-------------------------------------------------------------------------------------------------------------|
| 10.1               | Form of Promissory Note Schedule No. 08 issued to Oxford Finance Corporation, dated as of December 29, 2006 |
| 10.2               | Form of Promissory Note Schedule No. 09 issued to Oxford Finance Corporation, dated as of December 29, 2006 |